Abstract
AbstractThe Gs-protein-coupled adenosine A2Areceptor (A2AAR) represents an emerging drug target for cancer immunotherapy. The clinical candidate Etrumadenant was developed as an A2AAR antagonist with ancillary blockade of the A2BAR subtype. It constitutes a novel chemotype featuring a poly-substituted 2-amino-4-phenyl-6-triazolylpyrimidine core structure. Herein, we report two crystal structures of the A2AAR in complex with Etrumadenant, obtained with differently thermostabilized A2AAR constructs. This led to the discovery of an unprecedented interaction, a hydrogen bond of T883.36with the cyano group of Etrumadenant. T883.36is mutated in most A2AAR constructs used for crystallization, which has prevented the discovery of its interactions. In-vitro characterization of Etrumadenant indicated low selectivity versus the A1AR subtype, which can be rationalized by the structural data. These results will facilitate the future design of AR antagonists with desired selectivity. Moreover, they highlight the advantages of the new A2AAR crystallization construct devoid of ligand binding site mutations.
Publisher
Research Square Platform LLC
Reference50 articles.
1. International union of basic and clinical pharmacology. CXII: adenosine receptors: a further update;IJzerman AP;Pharmacol. Rev.,2022
2. Purinergic signalling and disorders of the central nervous system;Burnstock G;Nat. Rev. Drug Discov.,2008
3. Borea, P. A., Varani, K., Gessi, S., Merighi, S. & Vincenzi, F. The Adenosine Receptors (Springer International Publishing, Cham, 2018).
4. Agonist-dependent coupling of the promiscuous adenosine A2B receptor to Gα protein subunits;Voss JH;ACS Pharmacol. Transl. Sci.,2022
5. Characterization of human A2B adenosine receptors: radioligand binding, western blotting, and coupling to Gq in human embryonic kidney 293 cells and HMC-1 mast cells;Linden J;Mol. Pharmacol.,1999